AstraZeneca stock heads into the open after a 0.3 percent gain

At the close on September 7, 2026, AstraZeneca stock finished at GBP 120.42 in London, up 0.3 percent with a day range around the 120-pound mark as the FTSE 100 slipped slightly. Today, investors watch broader European health care sentiment.

AstraZeneca stock closed at GBP 120.42 on the London Stock Exchange on September 7, 2026, marking a 0.3 percent gain for the session from a prior close of GBP 120.06.

September 7, 2026 in numbers

AstraZeneca PLC (ISIN GB0009895292, London: AZN) ended the last completed session at 12,042.00 pence, up 36.00 pence or 0.30 percent compared with the previous close of 12,006.00 pence, according to closing data from Yahoo Finance. The stock traded within a narrow intraday range around the 12,000 pence level, with the recorded close sitting comfortably inside the day high and low as reported by market data services. While AstraZeneca added 1.5 percent earlier in the London session, it settled back to a more modest 0.3 percent gain by the close, still outperforming the headline FTSE 100 index, which slipped about 0.1 percent to roughly 10,822 points based on figures cited by London market coverage. This left AstraZeneca modestly ahead of the broader UK large-cap benchmark on September 7, 2026, underscoring relative strength in the health care segment amid cautious trading tied to rate expectations.

Sector reports from Proactive Investors noted that AstraZeneca was among the FTSE 100 constituents that advanced on September 7, 2026, with the stock gaining around 1.5 percent at one stage as peers in energy also moved higher. Later data from closing quote services confirmed that the stock finished with a 0.3 percent daily increase, aligning with the official London close figure of 12,042.00 pence. Against this backdrop, European share overviews from Reuters highlighted mixed performance across continental markets, with higher oil prices weighing on indices even as select pharmaceutical names showed resilience. Taken together, the last session framed AstraZeneca as a relatively steady outperformer compared with the slightly weaker FTSE 100, with no single company specific announcement dominating trading on September 7, 2026.

Today and the coming days

Today, September 8, 2026, AstraZeneca enters the new session without a newly reported earnings release or major scheduled corporate event flagged in the latest earnings calendars, but the stock remains sensitive to broader moves in European health care and rate expectations as outlined in recent regional market wraps. Recent analyst commentary from houses such as J.P. Morgan and Jefferies has reiterated positive views on AstraZeneca with updated price targets in early September, which can continue to shape sentiment as trading resumes. Over the next few days, investors are likely to track macroeconomic data and central bank signals that influence valuations for large pharmaceutical groups, alongside any pipeline or regulatory updates from sector peers that could read across to AstraZeneca. In this environment, the modest outperformance versus the FTSE 100 on September 7, 2026, provides a recent reference point for how AstraZeneca stock has been trading relative to the broader UK market ahead of today’s open.